Ani Pharmaceuticals (ANIP) Share-based Compensation (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Share-based Compensation data on file, last reported at $10.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 14.92% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $8.0 million (down 74.54% YoY), and the FY2025 full-year result was $6.6 million, down 77.37% from the prior year.
• Share-based Compensation rose to $10.2 million in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.2 million in Q1 2026 to a low of -$13.2 million in Q3 2025.
• A 5-year average of $3.7 million and a median of $4.3 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 4784.47% in 2024 and sank 276.7% in 2025, its largest moves.
• Tracing ANIP's Share-based Compensation over 5 years: stood at $483000.0 in 2022, then sank by 55.28% to $216000.0 in 2023, then surged by 3168.98% to $7.1 million in 2024, then tumbled by 80.22% to $1.4 million in 2025, then surged by 629.49% to $10.2 million in 2026.
• Business Quant data shows ANIP's Share-based Compensation at $10.2 million in Q1 2026, $1.4 million in Q4 2025, and -$13.2 million in Q3 2025.